Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2a, Partly Randomized, Open-label Trial to Investigate the Efficacy and Safety of an 8 or 12-Week Treatment Regimen of Simeprevir in Combination With Sofosbuvir in Treatment-Naive and Experienced Subjects With Chronic Genotype 4 Hepatitis C Infection

NCT02278419 is registered in ClinicalTrials.gov with Janssen-Cilag International NV as lead sponsor.

NCT NCT02278419
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02278419 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2a, Partly Randomized, Open-label Trial to Investigate the Efficacy and Safety of an 8 or 12-Week Treatment Regimen of Simeprevir in Combination With Sofosbuvir in Treatment-Naive and Experienced Subjects With Chronic Genotype 4 Hepatitis C Infection
Lead sponsor
Janssen-Cilag International NV
Phase
Phase 2
Overall status
Completed
Start date
December 31, 2014
Completion date
October 31, 2015
Enrollment
63 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

hepatitis c